Reproxalap(Reproxalap) - 药物靶点：RASP_在研适应症：干眼症，干眼综合征_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Reproxalap (USAN)、ADX-102、NS-2

+ [1]

靶点

RASP

作用方式

抑制剂

作用机制

RASP抑制剂(活性醛抑制剂)

治疗领域

眼部疾病

在研适应症

干眼症干眼综合征

非在研适应症

急性结膜炎变应性结膜炎非感染性前葡萄膜炎+ [3]

原研机构

Aldeyra Therapeutics, Inc.

在研机构

Aldeyra Therapeutics, Inc.

AbbVie, Inc.

非在研机构-

权益机构

AbbVie, Inc.

Aldeyra Therapeutics, Inc.Janssen Research & Development LLC

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H13ClN2O

InChIKeyGUHFUVLKYSQIOQ-UHFFFAOYSA-N

CAS号916056-79-6

关联

23

项与 Reproxalap 相关的临床试验

NCT06493604

/ Recruiting临床3期

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

开始日期2024-06-24

申办/合作机构

Aldeyra Therapeutics, Inc.

NCT06424444

/ Recruiting临床3期

A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap

开始日期2024-04-29

申办/合作机构

Aldeyra Therapeutics, Inc.

NCT06389214

/ Completed临床3期

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

开始日期2024-04-09

申办/合作机构

Aldeyra Therapeutics, Inc.

100 项与 Reproxalap 相关的临床结果

登录后查看更多信息

100 项与 Reproxalap 相关的转化医学

登录后查看更多信息

100 项与 Reproxalap 相关的专利（医药）

登录后查看更多信息

36

项与 Reproxalap 相关的文献（医药）

2022-08-01·Ophthalmology and therapy3区 · 医学

Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial

3区 · 医学

ArticleOA

作者: Nichols, Kelly K ; Starr, Christopher E ; Gomes, Paul J ; Brady, Todd C ; Cavanagh, Bill

INTRODUCTION:

This clinical trial assessed the activity of reproxalap, a novel reactive aldehyde species modulator, and estimated clinically relevant thresholds for changes in ocular itching and redness in an allergic conjunctivitis field trial.

METHODS:

This was a randomized, double-masked, vehicle-controlled phase 2 trial. Patients with ragweed-associated allergic conjunctivitis were assessed over 28 days in an environmental setting with approximately four doses per day of either 0.25% reproxalap, 0.5% reproxalap, or vehicle. Patients recorded ocular itching, redness, tearing, and eyelid swelling scores (each with a 0-4 scale, except for a 0-3 scale for swelling), and completed the Allergic Conjunctivitis Quality of Life Questionnaire at the beginning and end of the trial.

RESULTS:

Mixed model of repeated measures analysis demonstrated statistically lower itching and tearing scores (pooled P = 0.026 and P < 0.001, respectively) and numerically lower redness and eyelid swelling scores than vehicle on days when pollen exceeded the 95th percentile value. Using three anchor-based and three distribution-based approaches, the meaningful within-patient change and the between-group meaningful difference for patient-reported ocular itching and redness was estimated to be approximately 0.5. The most common treatment-emergent adverse event associated with reproxalap was transient irritation upon instillation.

CONCLUSION:

In a field clinical trial, reproxalap was well tolerated and superior to vehicle in reducing ocular itching on high-pollen days. The clinical meaningfulness threshold estimates of 0.5 units are among the first such calculations generated for the standard ocular itching and redness scores, providing important context for the clinical interpretation of clinical trials in allergic conjunctivitis.

2022-03-01·Molecular genetics and metabolism reports4区 · 医学

Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents

4区 · 医学

ArticleOA

作者: S'aulis, Dana ; Rizzo, William B ; Bailey, Zachary ; Dorwart, Elizabeth

Sjögren-Larsson syndrome (SLS) is a neurocutaneous disease caused by mutations in ALDH3A2 that result in deficient fatty aldehyde dehydrogenase (FALDH) activity and impaired fatty aldehyde and fatty alcohol oxidation. The pathogenesis of SLS is thought to involve accumulation of long-chain fatty aldehydes and alcohols and/or metabolically-related ether glycerolipids. Fatty aldehydes are particularly toxic molecules that can covalently react with proteins and certain amino-containing lipids such as phosphatidylethanolamine (PE), generating an unusual aldehyde adduct, N-alkyl-PE (NAPE). Using Faldh-deficient Chinese hamster ovary cells (FAA-K1A) as a cellular model for SLS, we investigated the ability of an aldehyde trapping agent, ADX-102 [2-(3-amino-6-chloro-quinolin-2-yl)-propan-2-ol], to mitigate the harmful effects of fatty aldehydes. FAA-K1A cells were protected from octadecanal (C18:0-al) induced cytotoxicity and apoptosis by ADX-102. Metabolism of C18:0-al to fatty alcohol (octadecanol) was also inhibited by ADX-102. FAA-K1A cells accumulated 5-fold more NAPE with C16- and C18-linked N-alkyl chains compared to wild-type cells, but NAPE levels decreased to normal after growth for 4 days with 50 μM ADX-102. Our results suggest that small aldehyde-reactive molecules, such as ADX-102, should be explored as novel therapeutic agents for SLS by preventing aldehyde adduct formation with critical cellular targets and inhibiting fatty aldehyde metabolism to fatty alcohol.

2021-10-01·American journal of ophthalmology2区 · 医学

Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial

2区 · 医学

Article

作者: Karpecki, Paul ; Clark, David ; Cavanagh, Bill ; Shields, Alan L ; Brady, Todd C ; Sheppard, John

PURPOSE:

To assess the post-acute activity and clinical utility of reproxalap, a novel reactive aldehyde species (RASP) inhibitor, versus vehicle in patients with seasonal allergic conjunctivitis.

DESIGN:

Parallel-group, double-masked, randomized Phase 3 trial.

METHODS:

Two topical ocular reproxalap concentrations (0.25% and 0.5%) were evaluated versus vehicle in patients with allergic conjunctivitis randomized 1:1:1 and treated with test article 10 minutes prior to conjunctival seasonal allergen challenge. The primary endpoint was area under the post-acute ocular itching score (range = 0-4) curve from 10 to 60 minutes after challenge. The key secondary endpoint was the proportion of subjects with ≥2 points improvement from their peak ocular itching score at baseline.

RESULTS:

A total of 318 patients were randomized at 11 US sites. Both concentrations of reproxalap (0.25% and 0.5%) achieved the primary endpoint (P < .0001 and P = .003, respectively) and the key secondary endpoint (P = .0005 and P = .02, respectively). Time to complete resolution of ocular itching was statistically faster for both reproxalap concentrations than for vehicle (P < .0001 and P = .001, respectively). No safety or tolerability concerns were noted. The most common adverse event was mild and transient instillation site irritation.

CONCLUSION:

Reproxalap was effective at reducing ocular itching in patients with allergic conjunctivitis. Reproxalap activity was clinically relevant, as assessed by responder-based and distributional analyses. ALLEVIATE represents one of the first allergic conjunctivitis Phase 3 trials of a novel mechanism of action in decades, and is unique among conjunctival allergen challenge trials in assessing clinical relevance with standard and validated techniques.

197

项与 Reproxalap 相关的新闻（医药）

2025-05-12

·生物制药小编

被拒两次再闯FDA，合作方仍选择观望

二次被拒一个多月后，Aldeyra Therapeutics准备再次敲击美国监管大门。近日，Aldeyra宣布其干眼症药物Reproxalap干眼室（一个让患者更容易出现干眼症状的不良环境）III期临床试验达到了主要终点目标，试验结果显示，暴露于干眼环境80-100分钟后，Reproxalap（0.25% ）组患者相比对照组（Vehicle）显著改善了眼部不适症状。公司认为，这些数据或许能解决上个FDA在完整回复函（CRL）中提出的担忧，公司计划再次向FDA提交Reproxalap的新药上市申请，时间大约在今年中期。会被批准通过吗?Reproxalap是一种小分子活性醛化物质抑制剂（RASP），通过抑制活性醛类物质，抑制眼表氧化应激反应，减轻干眼症相关的炎症。早在2022年11月，Aldeyra首次向FDA提交了新药上市申请，但是遭到了FDA的驳回，FDA认为Reproxalap的临床试验数据不足以证明有效性。2024年11月，基于一项干眼室Ⅲ期临床数据的鼓舞（2024年8月），Aldeyra再次提交了新药上市申请。然而，再次得到了FDA发出的CRL，理由与第一次一样，Reproxalap未能证明对治疗干眼症相关症状的有效性。两次被拒对Aldeyra的打击都相当大，第一次被拒，导致公司股价大跌近70%，二次被拒后又大跌73%。总体来看，Reproxalap对干眼症患者的疗效益处不够直接。最初，Aldeyra将眼睛发红（干眼症症状之一）设置为临床主要终点，但在之前进行的临床试验中，Reproxalap未能达到该目标，之后公司便把次要终点—Schirmer（泪液分泌测试）选定为临床主要终点，不过没能得到FDA的通过。之后，Aldeyra把Reproxalap的临床试验设置在了容易造成干眼的环境中，就目前看来，Reproxalap在干眼室中确实取得了积极结果，但Aldeyra并没有拿出改善干眼症本身症状的直接疗效证据。第三次的上市申请是否能得到FDA的通过颇为悬念。艾伯维在观望虽然Reproxalap的有效性仍然存在的疑问，但是现在也不得不硬着头皮再次申报上市。作为公司的核心管线，Reproxalap能否获批也关系着公司的命运。目前Reproxalap没有商业化产品，处于亏损状态，2024年公司净亏损－5585万美元，现金余额约1.01亿美元（截止2024年12月31日）。Aldeyra曾在财报中表示，公司的营收能力将取决于Reproxalap是否顺利开发、获批以及商业化。此外，Reproxalap能否获批还将决定公司能不能拿到2个亿美元的即时付款。2023年11月，Aldeyra与艾伯维达成了一项Co-license协议，艾伯维支付了100万美元定金（不可退还）获得了在美国共同开发和商业化Reproxalap的独家选择权。据协议条款，如果艾伯维行使选择权，将向Aldeyra支付1亿美元的预付款+以及未来高达3亿美元的里程碑付款，其中Reproxalap获批干眼症后，艾伯维就需支付Aldeyra 1亿美元里程碑付款。但是Reproxalap中间被拒也导致了艾伯维对于是否选择行权产生了迟疑，去年12月，艾伯维又花了500万美元把行权日延期至2025年4月30日。艾伯维是否会选择行权也存在相当大的不确定性。参考出处：https://www.businesswire.com/news/home/20250506374075/en/Aldeyra-Therapeutics-Achieves-Primary-Endpoint-in-Phase-3-Dry-Eye-Disease-Chamber-Trial-of-Reproxalap-and-Plans-NDA-Resubmissionhttps://endpts.com/aldeyra-plots-third-fda-filing-for-dry-eye-disease-drug-after-latest-phase-3-data/https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-0?sessionid=-1355142899三期数据成致命伤，2.6亿患者蓝海难救FIC药物

财报临床3期引进/卖出医药出海

2025-05-06

·药明康德

超4亿美元！礼来合作开发潜在“first-in-class”疗法；阿斯利康重磅小分子再获批准……

治疗神经退行性疾病，礼来合作开发潜在“first-in-class”疗法Alchemab Therapeutics公司今日宣布，已与礼来公司（Eli Lilly and Company）达成一项许可协议，合作开发Alchemab旗下用于治疗肌萎缩侧索硬化症（ALS）及其他神经退行性疾病的潜在“first-in-class”疗法ATLX-1282。本次交易总额最高可达4.15亿美元，包括未披露的预付款，以及潜在的发现、开发、商业化里程碑付款和销售分成。根据协议条款，Alchemab将负责将该项目推进至早期1期临床试验阶段，此后由礼来主导后续的全部开发和商业化工作。Alchemab的独特平台运用先进的机器学习和人工智能技术，解析人类免疫反应的复杂性，识别与对难治性疾病具有天然抗性的个体相关的特异性抗体。该平台依托超过6000例在神经退行性疾病、免疫学、肿瘤学和健康老龄化等领域中精心筛选与高度整理的患者样本，将实验室蛋白科学与生物学、机器学习、人类样本和专有数据分析方法有机融合，并借助超级计算机对数百万条抗体序列进行分析，进而发现具有独特作用机制的新靶点和抗体。通过研究，Alchemab在携带通常会导致额颞叶痴呆（FTD）突变、但却能维持健康的老年人群中，发现了一种抗体，并成功识别了其靶点。进一步研究证明了该靶点在神经保护方面的重要性，且适用于包括ALS和FTD在内的多种神经退行性疾病。一线治疗套细胞淋巴瘤，阿斯利康BTK抑制剂组合获欧盟委员会批准阿斯利康（AstraZeneca）今日宣布，其重磅布鲁顿氏酪氨酸激酶（BTK）抑制剂Calquence（acalabrutinib）与苯达莫司汀（bendamustine）和利妥昔单抗（rituximab）构成的组合疗法，已在欧盟（EU）获得批准，用于治疗不适合自体造血干细胞移植的初治套细胞淋巴瘤（MCL）成人患者。此次批准基于3期临床试验ECHO的积极结果。该研究结果曾在2024年欧洲血液学协会（EHA）年会上公布，并发表于Journal of Clinical Oncology。研究显示，与标准化疗联合免疫治疗相比，Calquence联合苯达莫司汀和利妥昔单抗可将疾病进展或死亡风险降低27%（HR=0.73；95% CI：0.57-0.94；p=0.016）。Calquence联合治疗组的中位无进展生存期（PFS）为66.4个月，标准治疗组为49.6个月。Calquence是一种第二代选择性BTK抑制剂，通过共价结合BTK来抑制其活性。在B细胞中，BTK信号通路可激活一系列促进B细胞增殖、迁移、趋化及黏附的关键下游信号通路。目前，Calquence已在多个国家和地区获批用于治疗慢性淋巴细胞白血病（CLL）、小淋巴细胞淋巴瘤（SLL）和MCL。潜在“first-in-class”干眼症疗法达3期临床主要终点，计划年中递交新药申请Aldeyra Therapeutics日前宣布，在研疗法reproxalap在治疗干眼症的一项3期随机、双盲、载体对照干眼舱试验中达到预设主要终点。该公司计划在年中向美国FDA递交新药申请（NDA）。数据显示，在眼部不适症状方面，reproxalap组（n=58）患者在进入干眼舱后80至100分钟期间的眼部不适评分（0‑100分）上，与载体对照组（n=58）相比具有统计学显著优势（最小二乘均值差为-6.5；95% CI：‑10.5, ‑2.5，P=0.002）。Aldeyra预计将在与FDA讨论后，于2025年年中重新提交NDA，预计审评周期为六个月。Reproxalap是一款潜在“first-in-class”的在研小分子活性醛抑制剂。活性醛含量会在眼部或系统性发炎时上升，造成眼睛发炎、泪水分泌降低、眼睛发红以及改变泪水内脂质组成，许多干眼症患者具有较高的活性醛水平。Reproxalap通过与活性醛共价结合，防止它们与蛋白产生相互作用，从而降低眼部的炎症。参考资料：[1] Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company. Retrieved May 6, 2025, from https://www.prnewswire.com/news-releases/alchemab-therapeutics-signs-landmark-415m-licensing-agreement-for-atlx-1282-with-eli-lilly-and-company-302446216.html[2] Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma. Retrieved May 6, 2025, from https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-eu-for-1l-mcl.html[3] Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission. Retrieved May 6, 2025, from https://www.businesswire.com/news/home/20250506374075/en/Aldeyra-Therapeutics-Achieves-Primary-Endpoint-in-Phase-3-Dry-Eye-Disease-Chamber-Trial-of-Reproxalap-and-Plans-NDA-Resubmission免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

引进/卖出临床3期临床2期临床1期免疫疗法

2025-05-06

·FierceBiotech

Aldeyra posts one hit, one miss for twice-rejected dry eye drug, plans FDA filing

Aldeyra Therapeutics plans to resubmit an approval application for its dry eye disease prospect in mid-2025 and expects a six-month FDA review. \n A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, preparing the biotech to seek approval for a candidate the FDA has rejected twice in recent years. Another phase 3 trial missed its primary endpoint, but Aldeyra said the data can still support its latest resubmission.Aldeyra first filed for FDA approval of reproxalap, which binds reactive aldehyde species, back in 2022. After the FDA demanded at least one additional symptom trial, the biotech started three studies and filed for approval again when the first readout was positive. The agency rejected the second submission in April and asked for positive data from at least one additional adequate and well-controlled study.The biotech shared top-line data from two studies after the market closed Monday, May 5. The dry eye chamber trial found reproxalap was statistically superior to the control on the primary endpoint, which looked at ocular discomfort.Aldeyra included data from another dry eye chamber trial in its second approval submission, but the FDA raised concerns about a baseline difference across treatment arms. The company said there were “no notable differences in baseline scores across treatment arms” in the second dry eye chamber trial and, as such, the study could potentially address the feedback the FDA shared in its complete response letter. Aldeyra plans to resubmit its approval application in mid-2025 and expects a six-month FDA review. The biotech is preparing to include data from the second dry eye chamber trial and from a recently finished field trial. Aldeyra shared top-line data from the field trial Monday, saying the trial was “numerically supportive of reproxalap and consistent with prior field trials, [but] did not reach statistical significance.”Draft FDA guidance states that chamber trials, which regulate temperature, air flow, humidity and other variables, and traditional environmental exposure studies can be acceptable in dry eye filings. Yet, there are no chamber data on the labels of the current crop of dry eye disease drugs. Aldeyra CEO Todd Brady, M.D., Ph.D., set out the pros and cons of relying on chamber data on a conference call with analysts in April.“It might be easier for the FDA to approve a drug based on a field trial simply because that\'s been the standard in the past. But I think there are advantages to having dry eye chamber data on our label,” Brady said. “I think our label would be compelling with either an additional field trial or a dry eye symptom trial from a dry eye chamber on the label.”

临床3期加速审批

100 项与 Reproxalap 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11309	-	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼症	申请上市	美国	Aldeyra Therapeutics, Inc.	2024-10-04
季节性过敏性结膜炎	临床3期	加拿大	Aldeyra Therapeutics, Inc.	2019-12-05
干眼综合征	临床3期	美国	Aldeyra Therapeutics, Inc.	2019-04-16
Sjogren-Larsson综合征	临床3期	美国	Aldeyra Therapeutics, Inc.	2018-07-18
急性结膜炎	临床3期	美国	Aldeyra Therapeutics, Inc.	2018-03-30
变应性结膜炎	临床3期	美国	Aldeyra Therapeutics, Inc.	2018-03-30
非感染性前葡萄膜炎	临床3期	美国	Aldeyra Therapeutics, Inc.	2017-04-26
季节性过敏性鼻炎	临床2期	加拿大	Aldeyra Therapeutics, Inc.	2015-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06493604 (BusinessWire) 人工标引	临床3期	干眼综合征	116	Reproxalap	繭鏇醖醖鬱窪觸繭簾膚(鬱衊範觸願蓋壓製糧繭): Difference (LS Mean) = ‑6.5 (95% CI, ‑10.5 ~ ‑2.5), P-Value = 0.002 达到	积极	2025-05-05
				vehicle
NCT03660878 (CTgov)	临床1/2期	季节性过敏性结膜炎	52	Reproxalap Ophthalmic Solution (0.25%) (Reproxalap Ophthalmic Solution (0.25%))	糧餘夢糧觸壓壓夢醖艱(壓築觸壓鏇艱蓋廠鹹構) = 襯艱築構膚糧鹹糧遞窪遞觸膚齋觸獵壓夢齋遞 (襯壓蓋衊淵糧網簾築蓋, 0.17) 更多	-	2025-04-08
				Vehicle Ophthalmic Solution (Vehicle Ophthalmic Solution)	糧餘夢糧觸壓壓夢醖艱(壓築觸壓鏇艱蓋廠鹹構) = 鹽觸壓襯鏇餘願齋艱鑰遞觸膚齋觸獵壓夢齋遞 (襯壓蓋衊淵糧網簾築蓋, 0.18) 更多
NCT05102409 (CTgov)	临床2期	干眼综合征	56	Reproxalap (Reproxalap)	淵夢淵衊襯簾夢糧鬱齋(鬱獵蓋淵選蓋衊遞範艱) = 鬱齋積鹽繭淵鹹遞淵艱餘遞網製襯構淵廠餘顧 (廠襯齋窪鹽醖遞顧餘糧, 0.21) 更多	-	2025-02-28
				Lifitegrast (Lifitegrast)	淵夢淵衊襯簾夢糧鬱齋(鬱獵蓋淵選蓋衊遞範艱) = 淵鬱窪構鏇製廠構艱繭餘遞網製襯構淵廠餘顧 (廠襯齋窪鹽醖遞顧餘糧, 0.25) 更多
NCT03494504 (CTgov)	临床3期	急性结膜炎 \| 变应性结膜炎	318	Reproxalap Ophthalmic Solution (0.25%) (Reproxalap Ophthalmic Solution (0.25%))	觸糧齋選糧網鹽窪膚淵(壓遞顧顧鏇鹽衊獵衊壓) = 艱餘餘簾鏇積鹹窪壓蓋餘築範鹽鏇淵獵夢窪鬱 (顧構構鹹壓壓夢鏇壓網, 3.3053) 更多	-	2025-02-11
				Reproxalap Ophthalmic Solution (0.5%) (Reproxalap Ophthalmic Solution (0.5%))	觸糧齋選糧網鹽窪膚淵(壓遞顧顧鏇鹽衊獵衊壓) = 構積鑰鹹襯遞鏇餘醖觸餘築範鹽鏇淵獵夢窪鬱 (顧構構鹹壓壓夢鏇壓網, 3.4552) 更多
NCT03879863 (RENEW, CTgov)	临床3期	干眼综合征	422	Reproxalap (Reproxalap Ophthalmic Solution (0.25%) QID)	膚選選願憲憲獵餘壓構(獵獵鏇選遞廠觸夢網鹽) = 鬱範壓衊鏇簾衊繭壓糧鏇淵廠鏇夢願鹽網夢製 (餘鏇壓築壓鹹憲淵醖鬱, 2.44) 更多	-	2025-01-23
				Vehicle Ophthalmic Solution QID (Vehicle Ophthalmic Solution QID)	膚選選願憲憲獵餘壓構(獵獵鏇選遞廠觸夢網鹽) = 繭觸齋獵襯淵鏇顧積構鏇淵廠鏇夢願鹽網夢製 (餘鏇壓築壓鹹憲淵醖鬱, 2.39) 更多
NCT03162783 (CTgov)	临床2期	干眼综合征	51	ADX-102 Ophthalmic Solution (0.1%) (ADX-102 Ophthalmic Solution (0.1%))	憲夢範遞遞積蓋廠範範(艱蓋膚壓遞蓋鬱餘願膚) = 窪餘憲獵獵衊襯憲艱獵鑰窪壓餘淵鏇廠範齋壓 (遞蓋觸餘窪糧範廠廠醖, 0.98) 更多	-	2025-01-16
				ADX-102 Ophthalmic Solution (0.5%) (ADX-102 Ophthalmic Solution (0.5%))	憲夢範遞遞積蓋廠範範(艱蓋膚壓遞蓋鬱餘願膚) = 淵遞夢範製願憲憲夢餘鑰窪壓餘淵鏇廠範齋壓 (遞蓋觸餘窪糧範廠廠醖, 0.75) 更多
NCT06389214 (BusinessWire) 人工标引	临床3期	干眼综合征	132	0.25% reproxalap	壓淵艱繭衊齋範鏇選範(獵選製蓋鹹壓獵糧構壓): P-Value = 0.004 达到更多	积极	2024-08-08
				vehicle
NCT05234554 (Phase III Clinical Trial, AAAAI2024)	临床3期	季节性过敏性结膜炎	-	Reproxalap Ophthalmic Solution (0.25%)	遞觸淵壓觸繭鹽襯鹹衊(積膚鏇鹽製選衊簾膚範) = 膚廠鑰網構餘構糧鏇憲範窪顧網簾夢夢淵壓糧 (製窪積壓廠壓築鑰蓋鏇 ) 更多	积极	2024-02-23
				Vehicle	遞觸淵壓觸繭鹽襯鹹衊(積膚鏇鹽製選衊簾膚範) = 壓範遞觸餘餘蓋衊顧淵範窪顧網簾夢夢淵壓糧 (製窪積壓廠壓築鑰蓋鏇 ) 更多
NCT05234554 (INVIGORATE-2, Corporate Publications) 人工标引	临床3期	季节性过敏性结膜炎	131	Reproxalap	艱積構淵淵觸願鏇窪鹽(願鹹構構遞顧襯鹽顧鑰): P-Value = <0.0001 达到更多	积极	2023-06-15
				Placebo
NCT03012165 (CTgov)	临床2期	变应性结膜炎	154	ADX-102 Ophthalmic Drops (0.5%) (ADX-102 Ophthalmic Drops (0.5%))	願淵憲鏇範糧鹽淵範壓(鏇簾壓製獵願範醖蓋鹽) = 繭壓範鏇獵蓋範廠艱顧壓選膚襯鏇鏇網襯選築 (夢構鏇糧夢獵窪醖鬱構, 簾齋醖範範衊網窪範製 ~ 醖鑰願鹽觸鹹積餘憲繭) 更多	-	2023-01-09
				ADX-102 Ophthalmic Drops (0.1%) (ADX-102 Ophthalmic Drops (0.1%))	願淵憲鏇範糧鹽淵範壓(鏇簾壓製獵願範醖蓋鹽) = 觸餘獵艱衊願鬱憲醖夢壓選膚襯鏇鏇網襯選築 (夢構鏇糧夢獵窪醖鬱構, 鏇繭網範顧選鑰廠糧壓 ~ 鏇觸齋築簾鹹觸製鏇選) 更多